P2-167Gemcitabine, Carboplatin, and Dexamethasone as Salvage Chemotherapy for Outpatients With Relapsed or Refractory Lymphoma

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy375.049
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Metronomic Chemotherapy and Palliative Radiotherapy as Salvage Treatment of Refractory or Relapsed Pediatric Solid Tumors

Current Oncology
Oncology
2016English

Efficiency and Safety of Stem Cell Mobilization Following GDP Salvage in Patients With Relapsed or Refractory Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Pet-Adapted Nivolumab +/- Ice as Initial Salvage Therapy in Relapsed/Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy